By targeting a mitochondrial pathway, the researchers at BPGbio have developed a therapy for hard-to-treat cancers, including glioblastoma.
Featured at DrugDiscoveryNews.com
Article by Stephanie DeMarco, Ph.D.
May 14, 2025
With all of the buzz around big data and artificial intelligence (AI) in drug discovery, the research team at the biopharma company BPGbio focuses on the source of that data — patients.
“We talk about patient centricity literally,” said Niven Narain, the Chief Executive Officer of BPGbio. “We start our discovery processes and our development by taking, for example, tissue from disease patients, from patients without the disease, tumor tissues, organ tissues, blood, urine, etc. And then, we have all the patient records.”
At the recent American Association for Cancer Research meeting (AACR 2025), Narain explained how his company’s focus on patients has powered their advances in drug discovery and development. This is especially true for their mitochondrial-targeted drug BPM31510, which is showing promise in hard-to-treat cancers including glioblastoma (GBM) and pancreatic cancer…
Full Story @ drugdiscoverynews.com: Hope for deadly brain cancers with a mitochondrial drug
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Media Contact: media@bpgbio.com
